« Back to Record
Citation APA

Gatell, J., Guaraldi, G. P., Masia, M., Gompels, M., De Wit, S., Florence, E., Esser, S., Raffi, F., Pozniak, A. L., Assoumou, L., Moyle, G., Waters, L., Johnson, M., Domingo, P., Fox, J., Martinez, E., & Stellbrink, H.-J. (2017). Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS, 31(18), 2503-2514. doi:10.1097/QAD.0000000000001675


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/261870

Gatell, J., Guaraldi, G. P., Masia, M., Gompels, M., De Wit, S., Florence, E., Esser, S., Raffi, F., Pozniak, A. L., Assoumou, L., Moyle, G., Waters, L., Johnson, M., Domingo, P., Fox, J., Martinez, E., & Stellbrink, H.-J. (2017). Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS, 31(18), 2503-2514. doi:10.1097/QAD.0000000000001675